Search PubMed⌕ Search

Biomedical subjects

G Turowski

Publications and source records attributed to G Turowski.

139 records · Page 8Linked to original sources
PubMedDate not supplied

HLA-ABC antigens in supraglottic cancer patients and their relationship with incidence and survival.

The frequency of HLA-ABC antigens in the total of 153 cases of supraglottic cancer of the larynx and in 118 and 37 patients from this group after 3 years and 5 or more years of survival respectively, was analysed. No significant differencies in the phenotype frequency class I HLA antigens in these patients were found, as compared with the frequency of of HLA, antigens in the healthy control population. The incidence of clinical stage I-III or IV did not affect the results, of the analysis. If the patients survived 5 or more years, the HLA-A31 antigen specificity was significantly more common at the beginning of the disease (Chi-square = 15,837; p < 0.005). A negative association for HLA-A11 in the patients with 3 years' survival was observed (Chi-square = 13,355; p < 0.025).

Female↗
PubMedDate not supplied

Initial observations on the administration of thymus extract (TFX) in patients with alimentary tract neoplasms.

The administration of thymus extract (TFX) has been performed in 35 patients suffering from malignancies of the alimentary tract. TFX, being a calf thymuses extract prepared by Jelenia Góra Drug Producers "Polfa" was given in the dose of 0.5 mg in 3 or 7-day intervals during several months. The immunological condition of patients was checked by many tests: E-rosettes, DLT (direct lymphocytotoxicity test) determination of absolute number of peripheral blood lymphocytes and skin tests (RT-23, PHA and TFX). Our observations revealed that TFX is biologically active also in humans, increases cell-mediated immunity and may restore the immune capability of patients operated due to malignancies of the alimentary tract.

Adult↗
PubMedDate not supplied

Immunological and patho-clinical observations of a patient with rectal carcinoma after long term administration of thymic extract (TFX).

TFX (Thymus Factor X) extract from calf thymuses, was given for the first time in Poland to the patient suffering from advanced rectal cancer with perforation to the peritoneal cavity, diffuse fecal peritonitis and multiple metastases to the liver. The immunological, clinical and histopathological observations of the patient for the period of 12 months of treatment are presented. The patient was given the biologically active thymus extract in the total amount of 14.2 mg in 34 subcutaneous injections initially in single dose of 0.1 mg and later on in amount of 0.5 mg. The remarkable restoration of the immunological reactivity of the patient from a total energy to the state of hyperreactivity has to be emphasized. It has been confirmed by the delayed hypersensitivity skin tests (Rt-23, PHA), the increase of the number of RFC (TEa and TEt rosette test with the SRBC), the diminishing of the autolymphocytotoxicity of the peripheral lymphocytes (evaluated by DTL) and also by the high level of the absolute number of circulating lymphocytes in the peripheral blood. The improvement of the clinical condition of the patient consisted in total regression of the inflammatory and functional changes in the respiratory and cardiovascular systems and also in the renal function. The regular rectal endoscopic examinations of the patient revealed the diminished size of the tumor and its unusual appearance described as an induration and sharp delimitation from the surrounding tissues. The histological examinations performed 5 times during the observation period of 11 months revaled the essential changes in the structure of the growth: the marked increase of the stroma with the signs of active proliferation, foci calcification and ossification. These changes were interpreted as extremely rare in the rectal cancer stroma and are considered to represent dystrophic calcification at the neoplastic foci followed by ossification. It should be also pointed out that twelve months survival of the patient with advanced rectal cancer and multiple metastases to the liver represents an unusually long rate in comparison to that generally accepted in the literature for this grade of rectal cancer advancement.

Adenocarcinoma↗